

Yasuhide Miyoshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1848558/publications.pdf>

Version: 2024-02-01

81
papers

1,011
citations

471509

17
h-index

526287

27
g-index

92
all docs

92
docs citations

92
times ranked

1392
citing authors

#	ARTICLE	IF	CITATIONS
1	The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer. <i>Asian Journal of Urology</i> , 2021, 8, 332-334.	1.2	2
2	A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer. <i>BJUI Compass</i> , 2021, 2, 105-114.	1.3	3
3	Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223. <i>BJUI Compass</i> , 2021, 2, 24-30.	1.3	5
4	Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients. <i>BJUI Compass</i> , 2021, 2, 31-38.	1.3	4
5	A lower psoas muscle index predicts a poorer prognosis in metastatic hormone-naïve prostate cancer. <i>BJUI Compass</i> , 2021, 2, 39-45.	1.3	4
6	A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 3323-3328.	2.2	7
7	Effectiveness and Feasibility of Up-Front Docetaxel Chemotherapy for Japanese Metastatic Hormone-Naïve Prostate Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1715-1716.	0.6	0
8	A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control. <i>Case Reports in Oncology</i> , 2020, 12, 688-692.	0.7	2
9	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. <i>World Journal of Urology</i> , 2020, 38, 2477-2484.	2.2	16
10	A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. <i>BMC Cancer</i> , 2020, 20, 919.	2.6	12
11	Prognostic Value of the LATITUDE and CHARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study. <i>BioMed Research International</i> , 2020, 2020, 1-7.	1.9	14
12	Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 8579-8588.	2.8	14
13	Cabozantinib in advanced renal cell carcinoma: A phase III, open-label, single-arm study of Japanese patients. <i>International Journal of Urology</i> , 2020, 27, 952-959.	1.0	17
14	Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer. <i>BMC Urology</i> , 2020, 20, 143.	1.4	1
15	Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. <i>Prostate</i> , 2020, 80, 824-830.	2.3	11
16	Re: Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 571-571.	1.0	0
17	A retrospective study on the possible systematic inflammatory response markers to predict the prognosis of patients with bladder cancer undergoing radical cystectomy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	5
18	Who is a bone-predominant patient to maximize clinical benefits of radium-223 dichloride?. <i>Journal of Clinical Oncology</i> , 2020, 38, 47-47.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 5891-5902.	2.8	22
20	The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday. <i>Case Reports in Oncology</i> , 2019, 12, 568-572.	0.7	4
21	Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib. <i>Case Reports in Oncology</i> , 2019, 12, 543-547.	0.7	0
22	Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 1161-1162.	1.0	4
23	Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. <i>Case Reports in Oncology</i> , 2019, 12, 548-553.	0.7	1
24	Inserting a Metallic Ureteral Stent Using an Antegrade Approach Freed a Patient from Nephrostomy Created due to Hydronephrosis Caused by Bladder Cancer. <i>Case Reports in Oncology</i> , 2019, 12, 560-563.	0.7	3
25	Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer. <i>Urologia Internationalis</i> , 2019, 103, 279-284.	1.3	11
26	Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis. <i>Case Reports in Oncology</i> , 2019, 12, 608-612.	0.7	8
27	Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia. <i>Case Reports in Oncology</i> , 2019, 12, 589-594.	0.7	3
28	Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019, 19, 331.	2.6	19
29	Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. <i>BioMed Research International</i> , 2019, 2019, 1-5.	1.9	25
30	The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-5.	1.9	4
31	Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer. <i>Urologia Internationalis</i> , 2019, 102, 37-42.	1.3	1
32	Management of urethral stricture: High-pressure balloon dilation versus optical internal urethrotomy. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O34-O37.	1.3	3
33	Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 32.	0.8	11
34	Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. <i>Molecular and Clinical Oncology</i> , 2018, 8, 587-591.	1.0	12
35	An infertile patient with Y chromosome b1/b3 deletion presenting with congenital bilateral absence of the vas deferens with normal spermatogenesis. <i>Clinical and Experimental Reproductive Medicine</i> , 2018, 45, 48-51.	1.5	2
36	Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>BMC Cancer</i> , 2018, 18, 501.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Fluorescent Light-Guided Cystoscopy with 5-ALA Aids in Accurate Surgical Margin Detection for TURBO: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 164-167.	0.7	1
38	Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure. <i>BMC Urology</i> , 2018, 18, 35.	1.4	15
39	Successful onco-testicular sperm extraction from a testicular cancer patient with a single testis and azoospermia. <i>Clinical and Experimental Reproductive Medicine</i> , 2018, 45, 44-47.	1.5	9
40	Value of bone scan index for predicting overall survival among patients treated with radium-223 for bone metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 216-216.	1.6	3
41	Evaluation of ability of low-molecular-weight protein tyrosine phosphatase expression to predict primary hormone therapy efficacy among men with metastatic hormone-naïve prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 316-316.	1.6	0
42	Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naïve metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 317-317.	1.6	0
43	Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 472-478.	1.9	13
44	RANK/RANKL expression in prostate cancer. <i>International Journal of Surgery Case Reports</i> , 2017, 30, 106-107.	0.6	6
45	Foreign body in the bladder: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 32, 22-24.	0.6	10
46	Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer. <i>Urologia Internationalis</i> , 2017, 99, 400-405.	1.3	5
47	Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 607.e9-607.e14.	1.6	5
48	Onco-testicular sperm extraction (onco-TESE) for bilateral testicular tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2017, 11, 139.	0.8	16
49	The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis. <i>BMC Urology</i> , 2017, 17, 49.	1.4	14
50	Port site recurrence after laparoscopic radical nephrectomy: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 151.	0.8	5
51	Inflammatory Myofibroblastic Tumor in the Bladder: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 554-558.	0.7	3
52	Ductal Adenocarcinoma of the Prostate: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 802-805.	0.7	3
53	The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer. <i>Current Urology</i> , 2017, 10, 166-168.	0.6	1
54	Xanthogranulomatous Pyelonephritis with Incomplete Double Ureter. <i>Case Reports in Medicine</i> , 2017, 1-3.	0.7	2

#	ARTICLE	IF	CITATIONS
55	A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. <i>BioMed Research International</i> , 2017, 2017, 1-4.	1.9	25
56	Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-5.	1.9	27
57	A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. <i>BMC Urology</i> , 2017, 17, 87.	1.4	40
58	Ureter metastatic castration-resistant prostate cancer: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 215.	0.8	2
59	Paraganglioma in the bladder: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 306.	0.8	19
60	Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. <i>Oncotarget</i> , 2016, 7, 14153-14160.	1.8	43
61	Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	14
62	Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy. <i>BioMed Research International</i> , 2016, 2016, 1-6.	1.9	15
63	Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. <i>BioMed Research International</i> , 2016, 2016, 1-5.	1.9	11
64	Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer. <i>Prostate</i> , 2016, 76, 376-382.	2.3	8
65	Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1042-1046.	1.3	13
66	Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 109.	2.6	29
67	Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. <i>BMC Cancer</i> , 2016, 16, 111.	2.6	35
68	Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer. <i>BMC Cancer</i> , 2016, 16, 396.	2.6	20
69	Epidermal Cyst in the Scrotum Successfully Treated while Preserving the Testis: A Case Report. <i>Case Reports in Oncology</i> , 2016, 9, 235-240.	0.7	3
70	Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naïve prostate cancer patients with bone metastases. <i>BMC Cancer</i> , 2016, 16, 128.	2.6	24
71	Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 48.	0.8	6
72	Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. <i>BMC Cancer</i> , 2016, 16, 185.	2.6	46

#	ARTICLE	IF	CITATIONS
73	Retroperitoneal Schwannoma in the Renal Hilum: A Case Report. <i>Case Reports in Oncology</i> , 2015, 8, 394-398.	0.7	2
74	Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. <i>BMC Cancer</i> , 2015, 15, 338.	2.6	35
75	Ureteroscopy-Assisted Biopsy for a Retroperitoneal Tumor: A Case Report. <i>Case Reports in Oncology</i> , 2015, 8, 279-284.	0.7	0
76	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. <i>Oncotarget</i> , 2015, 6, 32169-32176.	1.8	53
77	High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. <i>BMC Cancer</i> , 2014, 14, 717.	2.6	17
78	Androgen deprivation therapy prevents bladder cancer recurrence. <i>Oncotarget</i> , 2014, 5, 12665-12674.	1.8	101
79	Comparison of the Loss of Renal Function after Cold Ischemia Open Partial Nephrectomy, Warm Ischemia Laparoscopic Partial Nephrectomy and Laparoscopic Partial Nephrectomy Using Microwave Coagulation. <i>Current Urology</i> , 2013, 6, 118-123.	0.6	2
80	Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel. <i>PLoS ONE</i> , 2012, 7, e48186.	2.5	27
81	Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. <i>International Journal of Clinical Oncology</i> , 2005, 10, 182-186.	2.2	10